VantAI, an AI-driven protein interaction company spun out from Roivant Sciences, partnered with Halda Therapeutics in a deal exceeding $1 billion in potential value to accelerate discovery of selective proximity-based treatments for cancer and immunology. Leveraging VantAI’s Neo-1 diffusion model and NeoLink mass spectrometry platform, the collaboration aims to identify novel target-effector protein pairs for Halda's RIPTAC pipeline. The breakthrough approach addresses undruggable proteins by designing context-specific therapeutic protein complexes beyond traditional antibody targets.